Trial Profile
Brain-derived neutrophic factor genetic polymorphism Val66Met and response to fluoxetine and venlafaxine in patients with major depressive disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs Fluoxetine (Primary) ; Venlafaxine (Primary)
- Indications Major depressive disorder
- Focus Pharmacogenomic; Therapeutic Use
- 05 Nov 2010 New trial record.